The Technical Analyst
Nkarta, Inc. [NKTX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Nkarta, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
0.90% $7.86
America/New_York / 17 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 553.55 mill |
| EPS: | -2.40 |
| P/E: | -3.28 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 70.43 mill |
| Avg Daily Volume: | 1.056 mill |
| RATING 2024-04-17 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -3.28 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.56x |
| Company: PE -3.28 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-1.169 (-114.87%) $-9.03 |
| Date: 2024-04-18 |
| Expected Trading Range (DAY) |
|---|
|
$ 6.30 - 9.42 ( +/- 19.83%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-27 | Ra Capital Management, L.p. | Buy | 3 000 000 | Common Stock |
| 2024-03-27 | Ra Capital Management, L.p. | Buy | 3 000 031 | Pre- Funded Warrants (Right to Buy) |
| 2024-03-27 | George Simeon | Buy | 1 548 341 | Common Stock |
| 2024-03-27 | George Simeon | Buy | 451 659 | Common Stock |
| 2024-03-01 | Hastings Paul J | Sell | 12 358 | Common Stock |
| INSIDER POWER |
|---|
| 95.69 |
| Last 99 transactions |
| Buy: 11 537 422 | Sell: 349 926 |
Forecast:
16:00 - $7.86
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $7.86
Forecast 2: 16:00 - $7.86
Forecast 3: 16:00 - $7.86
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $7.86 (0.90% ) |
| Volume | 1.082 mill |
| Avg. Vol. | 1.056 mill |
| % of Avg. Vol | 102.53 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For NKTX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $10.85 | N/A | Active |
|---|
NKTX
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Last 10 Buy Signals
Latest Press Releases
2024-04-08 12:55:00 - Press Release
Glancy Prongay & Murray Llp, A Leading Securities Fraud Law Firm, Announces Investigation Of Nkarta, Inc. (nktx) On Behalf Of Investors
Los angeles--(business wire)--glancy prongay & murray llp (“gpm”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of nkarta, inc. (“nkarta” or the “company”) (nasdaq: nktx) investors concerning the company's possible violations of the federal securities laws. if you suffered a loss on your nkarta investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you.
2024-04-05 17:44:00 - Press Release
Investor Alert: Law Offices Of Howard G. Smith Announces Investigation Of Nkarta, Inc. (nktx) On Behalf Of Investors
Bensalem, pa.--(business wire)--law offices of howard g. smith announces an investigation on behalf of nkarta, inc. (“nkarta” or the “company”) (nasdaq: nktx) investors concerning the company's possible violations of federal securities laws. on march 21, 2024, nkarta announced that it had “deprioritized” its acute myeloid leukemia program, nkx101, stating that the “response rate was meaningfully lower than that from the first 5 previously reported patients.” on this news, nkarta's stock price f.
2024-04-05 15:35:00 - Press Release
The Law Offices Of Frank R. Cruz Announces Investigation Of Nkarta, Inc. (nktx) On Behalf Of Investors
Los angeles--(business wire)--the law offices of frank r. cruz announces an investigation of nkarta, inc. (“nkarta” or the “company”) (nasdaq: nktx) on behalf of investors concerning the company's possible violations of federal securities laws. if you are a shareholder who suffered a loss, click here to participate. on march 21, 2024, nkarta announced that it had “deprioritized” its acute myeloid leukemia program, nkx101, stating that the “response rate was meaningfully lower than that from the.
2024-04-03 16:02:00 - Press Release
Nkarta To Participate In Upcoming Investor Conferences
South san francisco, calif., april 03, 2024 (globe newswire) -- nkarta, inc. (nasdaq: nktx), a biopharmaceutical company developing engineered natural killer (nk) cell therapies, today announced its participation in two upcoming investor conferences:
2024-03-25 06:30:00 - Press Release
Nkarta Announces Pricing Of $240 Million Underwritten Offering
South san francisco, calif., march 25, 2024 (globe newswire) -- nkarta, inc. (nasdaq: nktx), a biopharmaceutical company developing engineered natural killer (nk) cell therapies, today announced the pricing of an underwritten offering of 21,010,000 shares of its common stock at a price of $10.00 per share and pre-funded warrants to purchase 3,000,031 shares of common stock. the pre-funded warrants are being sold at a price of $9.9999 per warrant, which represents the per share offering price for the common stock less the $0.0001 per share exercise price.
Latest News
2024-04-03 16:02:00 - GlobeNewsWire
Nkarta to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in two upcoming investor conferences:
2024-03-31 08:55:25 - 24/7 Wall Street
Huge Insider Buying From Buffett, an NFL Team Owner, a New CEO
Yet again, the Oracle of Omaha has bolstered his stake in a media giant's tracking stocks.
2024-02-29 06:30:00 - InvestorPlace
3 Silent Tech Titans-in-the-Making: Invest Before They Skyrocket
Among tech investments, the search for the next titan resembles a deep dive into the ocean for pearls. The periodic portfolio shifts toward solid tech contenders with high-yield potential as the digital space evolves.
2024-02-28 08:01:00 - GlobeNewsWire
Nkarta to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in three upcoming investor conferences:
2024-02-20 16:19:24 - InvestorPlace
Last Call! 7 Small-Cap Stocks Ready to Explode in Value
The article lists seven small-cap stocks for those looking for opportunities that promise exponential return potential. From innovative biotech firms to edgy technology providers, small-cap stocks are making waves in various industries, offering the chance to capitalize on their leads.
2024-02-08 09:32:00 - InvestorPlace
3 Under-the-Radar Stocks Set to Soar 300% by 2026
In the stock markets, where giants often steal the investment spotlight, hidden gems await discovery. Beyond the limelight lay under-the-radar stocks for 300% growth, teeming with potential and ready to soar to heights unimaginable to many investors.
2024-02-06 12:50:05 - InvestorPlace
3 Sleeper Stocks With Serious Potential to Make You a Millionaire
Amidst the bustle of large tech giants taking up the artificial intelligence ( AI ) space and news headlines of leading pharmaceutical juggernauts marking key development milestones, many quality stocks can easily fly under an investor's radar. Whether those are smaller companies producing innovative solutions or undervalued companies slowly working toward profitability, there lay hundreds of opportunities for investors that many investors have glazed over.
2024-02-05 12:41:35 - InvestorPlace
3 Once-in-a-Lifetime Biotech Stocks With Unprecedented Surge Potential
The biotech sector is one of my favorite sectors since it is not only constantly growing and with companies that are always doing wonderful research, products, and solutions, but it is also a sector that is constantly innovating and contributing to the health of the human being. If you want to participate as an investor in this sector and take advantage of companies that have great growth opportunities, here are three biotech stocks with potential that you can consider adding to your portfolio.
2024-02-04 08:00:00 - InvestorPlace
Unseen Giants: 3 Stocks Quietly Preparing for a 10X Surge
Some stocks silently position themselves for monumental bursts. These companies, spanning the semiconductor, healthcare and biotechnology sectors, are emerging as unseen giants with the potential for a 10X surge.
2023-12-19 10:11:12 - PennyStocks
Penny Stocks To Buy Now? 4 To Watch Before 2024
As we enter 2024, investors wonder if it will be another volatile year for stocks. Maybe we see some stabilization after 2023's ups and downs; maybe not.